Paz-ZuluetaMParás-BravoPCantarero-PrietoD, et al. A literature review of cost-of-illness studies on the economic burden of multiple sclerosis. Mult Scler Relat Disord2020; 43: 102162.
2.
KolasaK. How much is the cost of multiple sclerosis —Systematic literature review. Przegl Epidemiol2013; 67(1): 75–79, 157–160.
3.
AdelmanGRaneSGVillaKF. The cost burden of multiple sclerosis in the United States: A systematic review of the literature. J Med Econ2013; 16(5): 639–647.
4.
KobeltGThompsonABergJ, et al. European multiple sclerosis platform. New insights into the burden and costs of multiple sclerosis in Europe. Mult Scler2017; 23(8): 1123–1136.
5.
LunaGAlpingPBurmanJ, et al. Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies. JAMA Neurol2020; 77(2): 184–191.
6.
MocciaMAffinitoGRongaB, et al. Emergency medical care for multiple sclerosis: A five-year population study in the Campania Region (South Italy). Mult Scler2022; 28(4): 597–607.
7.
CharlsonMEPompeiPAlesKL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis1987; 40(5): 373–383.
8.
NgHSZhuFKingwellE, et al. Disease-modifying drugs for multiple sclerosis and subsequent health service use. Mult Scler. 2022; 28(4): 583–596.
9.
PeetersLMvan MunsterCEVan WijmeerschB, et al. Multidisciplinary data infrastructures in multiple sclerosis: Why they are needed and can be done!Mult Scler2019; 25(4): 500–509.
10.
Soelberg SorensenPGiovannoniGMontalbanX, et al. The multiple sclerosis care unit. Mult Scler2019; 25(5): 627–636.
11.
PapeixCGambottiLAssouadR, et al. Evaluation of an integrated multidisciplinary approach in multiple sclerosis care: A prospective, randomized, controlled study. Mult Scler J Exp Transl Clin2015; 1: 2055217315608864.
